Loading...
•
Mar 29
Haemonetics Q4 2025 Earnings Report
Haemonetics reported financial results for its fourth quarter and fiscal 2025.
Key Takeaways
Haemonetics delivered solid earnings growth in fiscal 2025, with record margin expansion and strong cash flow, driven by the performance of NexSys, TEG, and VASCADE technologies. The company is on track to achieve its four-year long-range plan goals for fiscal 2026.
Fourth quarter fiscal 2025 revenue was $330.6 million, a decrease of 3.7% compared to the prior year.
Net income for the fourth quarter fiscal 2025 was $58.0 million, an increase of 184.7% compared to the prior year.
Adjusted earnings per diluted share for the fourth quarter fiscal 2025 were $1.24, up 37.8% from the prior year.
Adjusted gross margin for the fourth quarter fiscal 2025 was 60.2%, an increase of 620 basis points from the prior year.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
For fiscal year 2026, Haemonetics expects total revenue growth between -3% and -6%, with adjusted operating margin between 26% and 27%, adjusted earnings per diluted share between $4.70 and $5.00, and free cash flow between $160 million and $200 million.
Positive Outlook
- Hospital segment revenue growth expected to be 8-11%.
- Organic revenue growth, ex-CSL, expected to be 6-9% for the total company.
- Adjusted operating margin expected to be 26-27%.
- Adjusted earnings per diluted share expected to be $4.70-$5.00.
- Free cash flow expected to be $160M-$200M.
Challenges Ahead
- Plasma segment revenue expected to decrease by 7-10%.
- Blood Center segment revenue expected to decrease by 23-26%.
- Total company reported revenue expected to decrease by 3-6%.
- Organic revenue growth for the total company expected to be -2% to 1%.
- Currency impact on total company revenue expected to be -1% to 0%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income